From Wikipedia, the free encyclopedia
  (Redirected from Diovan)
Jump to: navigation, search
Valsartan skeletal.svg
Valsartan ball-and-stick.png
Systematic (IUPAC) name
(S)-3-methyl-2-(N-{[2'-(2H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid
Clinical data
Trade names Diovan
AHFS/ monograph
MedlinePlus a697015
Licence data US FDA:link
  • US: D (Evidence of risk)
Legal status
Routes of
Pharmacokinetic data
Bioavailability 25%
Protein binding 95%
Biological half-life 6 hours
Excretion Renal 30%, biliary 70%
CAS Registry Number 137862-53-4 YesY
ATC code C09CA03
PubChem CID: 60846
DrugBank DB00177 YesY
ChemSpider 54833 YesY
KEGG D00400 YesY
Chemical data
Formula C24H29N5O3
Molecular mass 435.519 g/mol
 YesY (what is this?)  (verify)

Valsartan (trade name Diovan) is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.

Medical uses[edit]

Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.[1][2]

There is contradictory evidence with regard to treating people with heart failure with a combination of an angiotensin receptor blocker like valsartan and an angiotensin-converting enzyme inhibitor, with two major clinical trials (CHARM-additive and ValHeFt) showing a reduction in death, and two others (VALIANT and ONTARGET) showing no benefits, and more adverse effects including heart attacks.[1]


The packaging for valsartan includes a warning stating the drug should not be used with the renin inhibitor aliskiren. It also states the drug should not be used in people with kidney disease.[2]

Valsartan falls in FDA pregnancy category D and includes a black box warning for fetal toxicity.[2] Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be started.[2] The US labeling makes no recommendation regarding continuation or discontinuation of valsartan for breast-feeding mothers.[2] The Canadian labeling does not recommend use by nursing women.[3]

Side effects[edit]


Co-Diovan (Valsartan and hydrochlorothiazide)

The US prescribing information lists the following drug interactions for valsartan:

  • Other inhibitors of the renin-angiotensin system may increase the risks of low blood pressure, kidney problems, and hyperkalemia
  • Potassium sparing diuretics, potassium supplements, salt substitutes containing potassium may increase the risk of hyperkalemia.
  • NSAIDs may increase the risk of kidney problems and may interfere with blood pressure-lowering effects.
  • Valsartan may increase the concentration of lithium.[2]

Mechanism of action[edit]

Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure.[5]


In 2005, valsartan was prescribed more than 12 million times in the United States[citation needed], and global sales were around $6.1 billion in 2010.[6] The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012.[7][8]


In patients with impaired glucose tolerance, valsartan may decrease the incidence of developing diabetes mellitus type 2. However, the absolute risk reduction is small (less than 1 percent per year) and diet, exercise or other drugs, may be more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown.[9]

A prospective study released in 2010, based on 819,491 cases in U.S. Department of Veterans Affairs database from 2002 to 2006, demonstrated a significant reduction in the incidence and progression of Alzheimer's disease and dementia.[10]

See also[edit]


  1. ^ a b Randa, Hilal-Dandan (2011). "Chapter 26. Renin and Angiotensin". In Brunton, L. L.; Chabner, Bruce; Knollmann, Björn C. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0-07-162442-8. 
  2. ^ a b c d e f "Diovan prescribing information" (PDF). Novartis. 
  3. ^ Lexi-Drugs Online. "Valsartan". Lexi-Comp. 
  4. ^ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X. 
  5. ^ Marks JW (2007-02-15). "Valsartan, Diovan". MedicineNet. Retrieved 2010-03-04. 
  6. ^ "Novartis Annual Report". Novartis. 2010. Retrieved June 15, 2011.
  7. ^ Philip Moeller (April 29, 2011). "Blockbuster Drugs That Will Go Generic Soon". U.S.News & World Report. 
  8. ^ Eva Von Schaper (August 5, 2011). "Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires". Bloomberg. 
  9. ^ McMurray JJ, Holman RR, Haffner SM, et al. (April 2010). "Effect of valsartan on the incidence of diabetes and cardiovascular events" (PDF). The New England Journal of Medicine 362 (16): 1477–90. doi:10.1056/NEJMoa1001121. PMID 20228403. 
  10. ^ Li NC, Lee A, Whitmer RA, et al. (January 2010). "Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis" (PDF). BMJ 340: b5465. doi:10.1136/bmj.b5465. PMC 2806632. PMID 20068258. 

External links[edit]